Mr. Thomas Smeenk reports

HEMOSTEMIX CLOSES SALE OF 23RD ACP-01 THERAPY CONVERTIBLE DEBENTURE

Further to the prior news releases dated March 5, 2025, and June 26, 2025, Hemostemix Inc. has closed the sale of 15 ACP-01 therapy convertible debentures for proceeds of $517,230 (U.S.), subject to the approval of the TSX Venture Exchange.

"This is a breakthrough moment for Hemostemix," said Thomas Smeenk, chief executive officer. "With the approval of our therapy convertible debenture, we've ignited a new era -- one where VesCell therapy can be sold forward in blocks to clinics and investors and directly to high-net-worth individuals. The TCD is a game-changer: It streamlines production, aligns treatment schedules with physician time and powers our ability to scale fast -- without diluting shareholder equity. As the global leader in autologous stem cell therapy for heart and peripheral arterial disease, Hemostemix is now positioned to monetize innovation that generates increased shareholder valuation impacts," Mr. Smeenk said.

As an unsecured obligation of Hemostemix, each ACP-01 therapy convertible debenture is convertible into an ACP-01 therapy on a first purchased basis. The TCD is transferable, saleable, subject to a right of first refusal by Hemostemix, willable and convertible into common shares of the company at the option of the purchaser. The conversion price of the TCDs is 15.5 cents per common share. Each TCD collects interest at 6 per cent per annum, payable annually in shares of Hemostemix at the average closing price per share for the 10 days preceding Dec. 31 of each year. The TCD has a four-year maturity date of Dec. 31, 2029.

The proceeds from the TCD will be used for general working capital, corporate overhead, and research and development activities. The TCD is subject to a four-month-and-one-day hold from the date of issuance. In connection with the TCD offering, the company paid an arm's-length finder $59,171 and 356,298 finder common share purchase warrants, which allow the finder to purchase common shares at 15.5 cents per common share. The finder warrants have a one-year maturity date from the closing date.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01) and later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). Hemostemix has treated 498 patients, completed seven clinical studies of 318 subjects and published its results in nine peer-reviewed publications. ACP-01 is safe, clinically relevant and a statistically significant treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb-threatening ischemia.

We seek Safe Harbor.